sarepta gene therapy - Search News

News

Sarepta Will Resume Gene Therapy Shipments

Fierce Pharma · 9h

Vinay Prasad departs FDA amid conservative criticism, controversy over Sarepta gene therapy

Vinay Prasad, M.D., has left the FDA, less than three months into the role as director of the Center for Biologics Evaluation and Research, overseeing vaccines and cell and gene therapies. | Controversies,

Associated Press News on MSN · 2d

Sarepta will resume gene therapy shipments after FDA review of recent patient death

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy.

Reuters on MSN · 1d

Sarepta resumes shipping of gene therapy Elevidys to patients who can walk

Sarepta Therapeutics said on Monday it will resume shipping of its muscular disorder gene therapy to patients who can walk, sending the company's shares 59% higher in extended trading.

1don MSN

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

By Bhanvi Satija and Siddhi Mahatole (Reuters) -Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as ...

7h

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results